A profile on cobas® EGFR Mutation Test v2 as companion diagnostic for first-line treatment of patients with non-small cell lung cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A profile on cobas® EGFR Mutation Test v2 as companion diagnostic for first-line treatment of patients with non-small cell lung cancer

Published:2020-02-20 Issue:6 Volume:20 Page:575-582
ISSN:1473-7159
Container-title:Expert Review of Molecular Diagnostics
language:en
Short-container-title:Expert Review of Molecular Diagnostics

Author:

Torres Susana¹²³,González Álvaro¹,Cunquero Tomas Alberto Jacobo⁴,Calabuig Fariñas Silvia¹²³⁵^ORCID,Ferrero Macarena¹^ORCID,Mirda Danielle⁶,Sirera Rafael²³⁷^ORCID,Jantus-Lewintre Eloisa¹²³⁷^ORCID,Camps Carlos¹²³⁴⁸^ORCID

Affiliation:

1. Molecular Oncology Laboratory, General University Hospital Research Foundation, Valencia, Spain

2. CIBERONC, Madrid, Spain

3. Mixed Unit TRIAL CIPF-FIHGUV, Valencia, Spain

4. Medical Oncology Department, General University Hospital of Valencia, Valencia, Spain

5. Department of Pathology, Universitat de València, Valencia, Spain

6. George Washington University School of Medicine and Health Sciences, Washington, DC, USA

7. Department of Biotechnology, Universitat Politècnica de València, Valencia, Spain

8. Department of Medicine, Universitat de València, Valencia, Spain

Funder

General University Hospital Research Foundation

Publisher

Informa UK Limited

Subject

Genetics,Molecular Biology,Molecular Medicine,Pathology and Forensic Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737159.2020.1724094

Reference56 articles.

1. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)

2. Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

3. FDA Approval of Gefitinib for the Treatment of Patients with Metastatic EGFR Mutation–Positive Non–Small Cell Lung Cancer

4. Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer

5. First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comprehensive Genomic Analysis of Patients With Non–Small-Cell Lung Cancer Using Blood-Based Circulating Tumor DNA Assay: Findings From the BFAST Database of a Single Center in Taiwan;JCO Precision Oncology;2024-01

2. Oxford Nanopore Technology and its Application in Liquid Biopsies;Current Genomics;2023-11

3. Evaluating Stacked Methylation Markers for Blood-Based Multicancer Detection;Cancers;2023-10-01

4. Evaluation of the Analytical Performance of Oncomine Lung cfDNA Assay for Detection of Plasma EGFR Mutations;Genes;2023-06-02

5. Possible False Results With cobas^®EGFR Mutation Test v2 and Oncomine Dx Target Test forEGFRMutation;Anticancer Research;2023-05-29

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3